All Updates

All Updates

icon
Filter
Product updates
EDX Medical launches new products and services for assessing hereditary cancer risk
Precision Medicine
Jun 20, 2024
Last week:
M&A
Nscale acquires Kontena to enhance HPC and AI infrastructure capabilities
Generative AI Infrastructure
Yesterday
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Product updates
Together AI unveils new inference stack and endpoints for improved speed and efficiency
Generative AI Infrastructure
Jul 20, 2024
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Product updates
Micron Technology introduces high-performance MRDIMMs to improve bandwidth for AI and HPC applications
Generative AI Infrastructure
Jul 19, 2024
Management news
Bionano Genomics receives Nasdaq non-compliance notice; continues trading efforts
Precision Medicine
Jul 19, 2024
Funding
GRO Biosciences raises USD 60.3 million in Series B funding to advance lead program into clinical trials and expand GRObio pipeline
Precision Medicine
Jul 19, 2024
Management news
Yooz announces new appointments in C-Suite
Business Expense Management
Jul 19, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
Precision Medicine

Precision Medicine

Jun 20, 2024

EDX Medical launches new products and services for assessing hereditary cancer risk

Product updates

  • EDX Medical has revealed its new suite of products and services designed to evaluate hereditary cancer risk. The tests are developed based on comprehensive hereditary gremlin cancer testing designed to test the risk of cancer of family members of diagnosed cancer patients.

  • Its pan-cancer test is claimed to have 99% sensitivity and the ability to identify mutations in 70 genes known to be associated with cancers such as prostate, breast, colorectal, pancreatic, and ovarian cancer. The tests will be made available through specific NHS Genetic and Genomic Testing Centres and certain private healthcare providers in late 2024. The company will also be providing support services for healthcare professionals who will be using the tests.

  • UK-based EDX Medical Group is a digital diagnostics company focused on developing and delivering testing solutions. Its primary offerings include digital diagnostic products and services targeting cancer, cardiovascular disease, neurology, and infectious diseases. The company's approach combines advanced biological and digital technologies to improve disease risk detection and personalize disease management efficiently​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.